Beta Bionics, Inc. investors have until Nov. 3 to seek a lead role in a proposed lawsuit alleging misleading disclosures about its iLet insulin pump, a law firm said.
In an Oct. 19 notice, Schall, Brown & Schwartz LLP said the proposed class covers investors who bought the company’s common stock between July 30, 2025, and Feb. 24, 2026. The firm said investors need not seek the lead-plaintiff role to participate in any eventual recovery.
A public docket listing shows the suit against Beta Bionics and two executives was filed Sept. 4 in the federal court for California’s Central District. Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider are also named as defendants.
Schall says the complaint accuses the defendants of misleading shareholders about iLet and the extent of federal regulators’ concerns. Those allegations have not been established by a court.
The U.S. Food and Drug Administration (FDA) issued a warning letter Jan. 28 after inspecting the company’s Irvine, California, facility in June 2025. Its findings addressed complaint handling and corrective actions, as well as reports on devices and corrections.
The FDA said 107 complaints involving severe hypoglycemia or intervention to prevent it had been submitted as serious-injury medical device reports. It said Beta Bionics closed 56 related complaints without taking corrective action or documenting why none was needed. Those figures describe complaints and reporting practices, not a count of independently confirmed injuries.
Beta Bionics said in a Jan. 30 securities filing that the warning letter placed no limits on its existing manufacturing or sales. In a July 29 filing, the company said it had responded to the FDA and was still addressing the findings, with no date set for resolution.
That filing described iLet as Beta Bionics’ only commercialized device and said the business depended primarily on it. The company reported quality-system remediation expenses tied to the FDA findings of $562,000 in the first quarter and $62,000 in the second.
Beta Bionics plans to release third-quarter results after U.S. markets close Oct. 27 and hold an investor call at 4:30 p.m. ET. The firm’s stated deadline to seek lead-plaintiff appointment follows on Nov. 3.
